{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:06:40Z","timestamp":1780384000784,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008333","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000}}],"reference-count":114,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008333.pub2","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:55:14Z","timestamp":1601369714000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-cytokine targeted therapies for ANCA-associated vasculitis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Malgorzata M","family":"Bala","sequence":"additional","affiliation":[{"name":"Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa J","family":"Malecka-Massalska","sequence":"additional","affiliation":[{"name":"Rheumatology Department; Provincial Hospital, Radzyn Podlaski; Lublin Poland"},{"name":"Physiology Department; Medical University of Lublin; Lublin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Koperny","sequence":"additional","affiliation":[{"name":"Systematic Reviews Unit; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna F","family":"Zajac","sequence":"additional","affiliation":[{"name":"Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics; Jagiellonian University Medical College; Krakow Poland"},{"name":"Systematic Reviews Unit; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw D","family":"Jarczewski","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Szczeklik","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"10.1002\/14651858.CD008333.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Jayne D Blockmans D Luqmani R Ji B Green Y AB0692\u2005Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers Annals of the Rheumatic Diseases 2018 1488","DOI":"10.1136\/annrheumdis-2018-eular.6474"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"952-963","DOI":"10.1002\/art.40802","article-title":"Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Jayne D Blockmans D Ji B Green Y Hall L Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study. Arthritis and Rheumatology 2017","DOI":"10.1136\/annrheumdis-2018-eular.6474"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0004|cit4","unstructured":"A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis clinicaltrials.gov\/ct2\/show\/study\/NCT01663623?term=BREVAS&rank=1"},{"issue":"1 suppl 64","key":"10.1002\/14651858.CD008333.pub2-BIB0005|cit5","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"Menthon","year":"2011","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CPM.0000000000000237","article-title":"Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?","volume":"24","author":"Krishna","year":"2017","journal-title":"Clinical Pulmonary Medicine"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0007|cit7","first-page":"iii15","article-title":"Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis","volume":"56","author":"Smith","year":"2017","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0008|cit8","unstructured":"Steinfeld J Bradford ES Brown J Mallett S Yancey SW Wechsler ME Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial Arthritis Rheumatol 2017"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0009|cit9","first-page":"A3012","article-title":"Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo","volume":"197","author":"Steinfeld","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","journal-title":"J Allergy Clin Immunol"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0011|cit11","first-page":"107","article-title":"Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial","volume":"195","author":"Wechsler","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"20","key":"10.1002\/14651858.CD008333.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0013|cit13","unstructured":"Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS\/WG) in a randomized clinical trial Cleveland Clinic Journal of Medicine 2002 69"},{"issue":"7","key":"10.1002\/14651858.CD008333.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD008333.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.30394","article-title":"Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener\u2019s) long-term follow-up of a multicenter longitudinal cohort","volume":"63","author":"Silva","year":"2011","journal-title":"Arthritis & Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008333.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"Design of the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"23","author":"WGET Research Group","year":"2002","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial Research","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jclinpath-2016-203875","article-title":"Update on systemic vasculitides","volume":"70","author":"Anwar","year":"2017","journal-title":"Journal of Clinical Pathology"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"193\u2013206","DOI":"10.1007\/s40674-017-0073-z","article-title":"Current and future treatment options for eosinophilic granulomatosis with polyangiitis","volume":"3","author":"Berti","year":"2017","journal-title":"Current Treatment Options in Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0021|cit21","unstructured":"BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC) Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01598857 2012"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNFalpha blockade in relapsing vasculitis","volume":"61","author":"Booth","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jama.298.6.655","article-title":"Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review","volume":"298","author":"Bosch","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.ajkd.2011.03.006","article-title":"Maintenance immunosuppression in antineutrophil cytoplasmic antibody - associated vasculitis","volume":"57","author":"Cattran","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0026|cit26","unstructured":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis Clinicaltrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01275287?id=NCT01275287&rank=1"},{"issue":"12","key":"10.1002\/14651858.CD008333.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3899\/jrheum.160456","article-title":"Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis","volume":"43","author":"Fraser","year":"2016","journal-title":"The Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD008333.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.revmed.2005.05.019","article-title":"Are anti-TNFAb indicated in systemic necrotizing vasculitides?","volume":"26","author":"Guillevin","year":"2005","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"1 Suppl 70","key":"10.1002\/14651858.CD008333.pub2-BIB0029|cit29","first-page":"S62","article-title":"Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome","volume":"30","author":"Herrmann","year":"2012","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ndt\/gfv060","article-title":"Twenty-five years of European Union collaboration in ANCA-associated vasculitis research","volume":"30","author":"Jayne","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","article-title":"Sustained response to mepolizumab in refractory Churg-Strauss syndrome","volume":"125","author":"Kahn","year":"2010","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/j.1755-3768.2009.01546.x","article-title":"Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment","volume":"88","author":"Kontkanen","year":"2010","journal-title":"Acta Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CPM.0000000000000237","article-title":"Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?","volume":"24","author":"Krishna","year":"2017","journal-title":"Clinical Pulmonary Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.11475","article-title":"A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group","volume":"50","author":"Lamprecht","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000082214","article-title":"TNF-inhibitors in Wegener's granulomatosis","volume":"28","author":"Lamprecht","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1440-1843.2010.01884.x","article-title":"Difficult asthma and Churg-Strauss-like syndrome: a cautionary tale","volume":"16","author":"Lau","year":"2011","journal-title":"Respirology"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-200868060-00003","article-title":"Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"68","author":"Lee","year":"2008","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD008333.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.intimp.2015.04.023","article-title":"Biological drugs in ANCA-associated vasculitis","volume":"27","author":"Lutalo","year":"2015","journal-title":"International Immunopharmacology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0039|cit39","unstructured":"A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome clinicaltrialsregister.eu\/ctr-search\/trial\/2006-001791-20\/DE\/"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.lpm.2013.02.001","article-title":"The future of international clinical trials in vasculitis","volume":"42","author":"Merkel","year":"2013","journal-title":"Presse Medicale"},{"issue":"5","key":"10.1002\/14651858.CD008333.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD008333.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.lpm.2013.01.006","article-title":"Eosinophilic granulomatosis with polyangiitis: future therapies","volume":"42","author":"Moosig","year":"2013","journal-title":"Presse Medicale"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/157339511797535081","article-title":"Clinical trials in ANCA associated vasculitis","volume":"7","author":"Mukhtyar","year":"2011","journal-title":"Current Immunology Reviews"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/annrheumdis-2016-eular.6422","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Mukhtyar","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1871528113666140702094456","article-title":"Biologics for ANCA-associated vasculitis","volume":"13","author":"Murgia","year":"2014","journal-title":"Inflammation & Allergy Drug Targets"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Niles J Allen N Block JA Koening CL Langford CA Abril A Lee AS Merkel PA Mertz LE Monach PA Moreland LW Nachman PH Peikert T Spiera RF Wallace D Erblang F Cascino MD Duncombe P Malik V Brunetta P Safety following initiation of rituximab in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA): Interim analysis of the rituximab in ANCA-associated vasculitis registry (RAVER) Annals of the Rheumatic Diseases 2017 318","DOI":"10.1136\/annrheumdis-2017-eular.1177"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.monrhu.2017.03.005","article-title":"Biologic treatment prospects in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"84","author":"Pu\u00e9chal","year":"2017","journal-title":"Revue du Rhumatisme Monographies"},{"issue":"2","key":"10.1002\/14651858.CD008333.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0049|cit49","unstructured":"British Society for Rheumatology and British Health Professionals Rheumatology 2013 - British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting 2013 Rheumatology 2013 Suppl 1:i1 173"},{"issue":"9","key":"10.1002\/14651858.CD008333.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/rheumatology\/keg295","article-title":"Infliximab efficiency in refractory Wegener's granulomatosis","volume":"42","author":"Rozin","year":"2003","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaci.2007.10.040","article-title":"Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment","volume":"121","author":"Ruppert","year":"2008","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14728214.2016.1210601","article-title":"Moving towards new treatments for vasculitis","volume":"21","author":"Saadoun","year":"2016","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"5","key":"10.1002\/14651858.CD008333.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3109\/14397595.2015.1021138","article-title":"Corticosteroid- and cyclophosphamide-free treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis using tocilizumab","volume":"25","author":"Sakai","year":"2015","journal-title":"Modern Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.lpm.2013.02.038","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) with no initial Five-Factor Score-defined poor-prognosis factors (FFS = 0): Baseline factors associated with cytotoxic agent and immunomodulator prescription","volume":"42","author":"Samson","year":"2013","journal-title":"Presse Medicale"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Samson M Puechal X Devilliers H Ribi C Cohen P Bienvenu B Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors Autoimmunity Reviews 2014 13 2 197 205","DOI":"10.1016\/j.autrev.2013.10.001"},{"issue":"41","key":"10.1002\/14651858.CD008333.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1055\/s-2006-951364","article-title":"Biologicals in the treatment of rheumatic diseases","volume":"131","author":"Scherer","year":"2006","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Seror R Pagnoux C Ruivard M Landru I Wahl D Riviere S Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial Annals of the Rheumatic Diseases 2010 69 12 2125 30","DOI":"10.1136\/ard.2010.131953"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11926-012-0290-2","article-title":"TNF-alpha blocker therapy and solid malignancy risk in ANCA-associated vasculitis","volume":"14","author":"Silva","year":"2012","journal-title":"Current Rheumatology Reports"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Silva L Blanco R Mart\u00ednez-Taboada V Loza E Pego JM R\u00faa-Figueroa I AB0761 TNF inhibitors for the treatment of ANCA associated vasculitis: A systematic review Annals of the Rheumatic Disease 2013 682","DOI":"10.1136\/annrheumdis-2012-eular.761"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semarthrit.2013.07.010","article-title":"Biological therapy for systemic vasculitis: a systematic review","volume":"43","author":"Silva-Fernandez","year":"2014","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0000000000000382","article-title":"Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis","volume":"29","author":"Singer","year":"2017","journal-title":"Current Opinion in Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0062|cit62","first-page":"93","article-title":"Anti-TNF alpha agents in vasculitis","volume":"130","author":"Solans Laque","year":"2008","journal-title":"Medicina Cl\u00ednica"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2009.05.023","article-title":"Role of omalizumab and steroids in Churg-Strauss syndrome","volume":"124","author":"Spina","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157339710803140210193939","article-title":"Therapeutic implications of tocilizumab, a humanized anti-interleukin-6 receptor antibody, for various immune-mediated diseases: An update review","volume":"8","author":"Tanaka","year":"2012","journal-title":"Current Rheumatology Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrrheum.2010.19","article-title":"Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE?","volume":"6","author":"Watts","year":"2010","journal-title":"Nature reviews. Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Westman K SP0067 Long term outcomes in systemic vasculitis Annals of the Rheumatic Disease 2013 17","DOI":"10.1136\/annrheumdis-2012-eular.1542"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0067|cit67","unstructured":"A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis clinicaltrials.gov\/ct2\/show\/NCT00482066"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0068|cit68","unstructured":"Phase I\/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis clinicaltrials.gov\/ct2\/show\/NCT00001901"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0069|cit69","unstructured":"A Randomized Trial Examining the Use of Daclizumab in Wegener's Granulomatosis clinicaltrials.gov\/ct2\/show\/NCT00040248"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0070|cit70","unstructured":"Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000024574"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0071|cit71","unstructured":"Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE) clinicaltrials.gov\/ct2\/show\/NCT02108860"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Gopaluni S Goymer D McClure M Cahill H Broadhurst E Alemtuzumab for relapsing and refractory primary systemic vasculitis - A trial of efficacy and safety (aleviate): A randomised open-label phase ii clinical trial Rheumatology 2019 kez063.026","DOI":"10.1093\/rheumatology\/kez063.026"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0073|cit73","unstructured":"Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy clinicaltrials.gov\/ct2\/show\/NCT01405807?id=NCT01405807&rank=1"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0074|cit74","unstructured":"Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03967925?cond=ANCA+Associated+Vasculitis&draw=2&rank=12"},{"issue":"7","key":"10.1002\/14651858.CD008333.pub2-BIB0075|cit75","first-page":"1371","article-title":"Refractory polyarteritis nodosa successfully treated with infliximab","volume":"32","author":"Al-Bishri","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","article-title":"Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab","volume":"45","author":"Berti","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0077|cit77","unstructured":"Visual Rx Dr. Christopher Cates EBM web site 2008"},{"issue":"42","key":"10.1002\/14651858.CD008333.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10420","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD008333.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [see comment]","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780390112","article-title":"The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources","volume":"39","author":"Cotch","year":"1996","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","article-title":"Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d'Etudes et de Recherchesur les Maladies Orphelines Pulmonaires and the European Respiratory SocietyTaskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"16","author":"Cottin","year":"2017","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0082|cit82","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008333.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1681\/ASN.2005121359","article-title":"Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases","volume":"17","author":"Feldmann","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008333.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane musculoskeletal group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008333.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/rheumatology\/kei259","article-title":"The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region","volume":"45","author":"Gibson","year":"2006","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008333.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/berh.2002.0260","article-title":"Systemic vasculitides","volume":"16","author":"Gonzalez-Gay","year":"2002","journal-title":"Best Practice & Research in Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0088|cit88","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime, Inc.) 2015"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/1529-0131(200104)44:4<921::AID-ANR149>3.0.CO;2-4","article-title":"IgG from myeloperoxidase\u2013antineutrophil cytoplasmic antibody\u2013positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3\u2013antineutrophil cytoplasmic antibody\u2013positive patients","volume":"44","author":"Harper","year":"2001","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0090|cit90","unstructured":"Higgins JPT Altman DG Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from cochrane.handbook.org"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0091|cit91","unstructured":"Higgins JPT Deeks JJ Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0092|cit92","unstructured":"Higgins JPT Chapter 7: Selecting studies and collecting data Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/01.ASN.0000016442.33680.3E","article-title":"ANCA-positive vasculitis","volume":"13","author":"Kamesh","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2332\/allergolint.14-RAI-0778","article-title":"Current concept and epidemiology of systemic vasculitides","volume":"63","author":"Katsuyama","year":"2014","journal-title":"Allergology International"},{"issue":"6","key":"10.1002\/14651858.CD008333.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD008333.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008333.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/art.20077","article-title":"Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate","volume":"51","author":"Mahr","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008333.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management","volume":"26","author":"Mahr","year":"2014","journal-title":"Current Opinion in Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00281-014-0436-6","article-title":"The immunopathology of ANCA-associated vasculitis","volume":"36","author":"McKinney","year":"2014","journal-title":"Seminars in Immunopathology"},{"issue":"7","key":"10.1002\/14651858.CD008333.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0104|cit104","unstructured":"Merkel PA Matteson EL Ramirez Curtis M Overview of and approach to the vasculitides in adults In: Post TW (editor). UpToDate, Waltham, MA."},{"issue":"339","key":"10.1002\/14651858.CD008333.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"21","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0106|cit106","unstructured":"Review Manager 5 (RevMan 5) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0107|cit107","unstructured":"Riminton S Lymphocyte directed biologic therapies for primary systemic necrotizing vasculitis (registered title) Available from:cochrane.org\/title\/lymphocyte-directed-biologic-therapies-for-primary-systemic-necrotizing-vasculitis"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0108|cit108","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11. Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0109|cit109","unstructured":"Sch\u00fcnemann H Oxman AD Vist GE Higgins JBT Deeks JJ Glasziou P Guyatt GH Chapter 12. Interpreting results and drawing conclusions.In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD008333.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semarthrit.2013.07.010","article-title":"Biological therapy for systemic vasculitis: a systematic review","volume":"43","author":"Silva-Fern\u00e1ndez","year":"2014","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008333.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.rbr.2017.05.002","article-title":"Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis","volume":"57 Suppl 2","author":"Souza","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed."},{"key":"10.1002\/14651858.CD008333.pub2-BIB0112|cit112","unstructured":"Sterne JAC Egger M Chapter 10. Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD008333.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD008333.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Annals of Rheumatic Diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:18:56Z","timestamp":1780381136000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008333.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":114,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008333.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}